Is Jounce Therapeutics, Inc. (JNCE) a Buy, Sell, or Hold?
NASDAQ : JNCE
Jounce Therapeutics, Inc.
$1.88 USD
$0 (0.0%)
- Volume
- 11.6M
- Average Volume
- 3.47M
- Market Capitalization
- $98.95M
- P/E Ratio
- -1.90
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.37
- Year Low
- $0.58
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.37
Company Overview
NASDAQ
Kimberlee Cobleigh Drapkin CPA
Biotechnology
Healthcare
JNCE
141
US
USD
Liquidity Metrics
0.05
8.37
8.37
6.39
0.00
Sales & Valuation
$82M
1.21
0.53
-3.32
-0.58
Profitability
-$0.99
-$50.92M
-62.10%
-61.93%
-25.03%
-23.96%
P/E Metrics
-1.90
0.09
0.09
Analyst Price Target & Rating
0/5
10 Analysts
%
Financial Health Scores
0.64
3/9
$173.66M
$212.55M
$29.44M
-$52.24M
Key Metrics (TTM)
-$41.6M
-0.51
0.83
8.37
-25.03%
-27.05%
-52.41%
-30.11%
0 days
Company Executives
| Name | Title |
|---|---|
| Jacquelyn Fahey Sandell | Chief Legal Officer & Corporation Sec. |
| Stephen G. Farrand | Chief Technical Officer |
| Eric Laub | Vice President of Investor Relations, Corporation Communications & Media Relations |
| Kimberlee Cobleigh Drapkin | Pres, Chief Financial Officer & Treasurer |
| Komal Joshi | Head of Investor Relations & Strategic Fin. |
Poll Results
No votes yet today — be the first to share your view!
About Jounce Therapeutics, Inc. (NASDAQ:JNCE) Stock
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered t ... o selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Jounce Therapeutics, Inc. (JNCE) stock price?
-
Jounce Therapeutics, Inc.(NASDAQ:JNCE) stock price is $1.88 in the last trading session. During the trading session, JNCE stock reached the peak price of $5.37 while $0.5773 was the lowest point it dropped to. The percentage change in JNCE stock occurred in the recent session was 0.0% while the dollar amount for the price change in JNCE stock was $0.
-
JNCE's industry and sector of operation?
-
The NASDAQ listed JNCE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of JNCE?
-
Jacquelyn Fahey Sandell | Chief Legal Officer & Corporation Sec.
Stephen G. Farrand | Chief Technical Officer
Eric Laub | Vice President of Investor Relations, Corporation Communications & Media Relations
Kimberlee Cobleigh Drapkin | Pres, Chief Financial Officer & Treasurer
Komal Joshi | Head of Investor Relations & Strategic Fin. -
How many employees does JNCE have?
-
Number of JNCE employees currently stands at 141. JNCE operates from 780 Memorial Drive, Cambridge, MA 02139, US.
-
Link for JNCE official website?
-
Official Website of JNCE is: https://jouncetx.com
-
How do I contact JNCE?
-
JNCE could be contacted at phone #857 259 3840 and can also be accessed through its website. JNCE operates from 780 Memorial Drive, Cambridge, MA 02139, US.
-
How many shares of JNCE are traded daily?
-
The average number of JNCE shares traded daily for last 3 months was 3.47M.
-
What is the market cap of JNCE currently?
-
The market value of JNCE currently stands at $98.95M with its latest stock price at $1.88